While the most most optimal is is the first sample collection and follow-up-up on a fully ved protocol, this r equir res costly and y biomarker assessment, who's the hampers timely deployment of biomarkers. As an alternative, retrospective s of samples archived as part of the previously ded dd fod fod trials ive-retrospective design is proposed to shorten the time frame while assying quality of the study study (16). Another solution is to develop a biobank in who biolys and complete clinical annotations are the ation saiacumul Ated ed on well-defined protocols. However, in part due to the complex and heterogeneous nature of cancer, it hasbecome insily body, that there is a need for larger integrated biobanks (32, 33) who need careful development and the eu to public ing guidelines
正在翻譯中..
![](//zhcntimg.ilovetranslation.com/pic/loading_3.gif?v=b9814dd30c1d7c59_8619)